Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat Toby M. Maher1,2* and Mary E. Strek3 Correspondence: t.maher@rbht.nhs.uk1National Institute for Health Research Respiratory Clinical Research Facility, Royal Brompton and Harefield NHS Foundation Trust, Sydney Street, London,SW3 6NP, UK2Fibrosis Research Group, National Heart and Lung Institute, Imperial College, Cale Street, London SW3 6LY, UKFull list of […]
| M | T | W | T | F | S | S |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | ||||
| 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| 11 | 12 | 13 | 14 | 15 | 16 | 17 |
| 18 | 19 | 20 | 21 | 22 | 23 | 24 |
| 25 | 26 | 27 | 28 | 29 | 30 | |
#BreathingLife #CurePF #PFMonth #pulmonaryfibrosis #UseYourLungs ACEi Action for Pulmonary Fibrosis Angiotensin-converting enzyme inhibitor Angiotensin II receptor blocker Angiotensin modulators Angiotensin peptides Antifibrotic therapies CD1d molecules chronic inflammation Exercise Exercise-based pulmonary rehabilitation fibroblasts fibrosis Forced vital capacity FVC Idiopathic pulmonary fibrosis Interstitial lung disease IPF Macrophages Natural killer T cells NKT Pathogenesis Pleuroparenchymal fibroelastosis Post hoc analysis PPFE Pulmonary Fibrosis Pulmonary Fibrosis Research and Education Hub Pulmonary rehabilitation Slower disease progression tissue fibrosis Upper lobe fibroelastosis